CD137L CD8a, Fusion Protein

Katalog-Nummer C2548-38A-25ug

Size : 25ug

Marke : US Biological

Weitere Informationen anfordern

Contact local distributor :


Telefonnummer : +1 850 650 7790


C2548-38A CD137L CD8a, Fusion Protein

Clone Type
Polyclonal
Grade
Affinity Purified
Applications
E FC
Shipping Temp
Blue Ice
Storage Temp
4°C Do Not Freeze

Human CD137 Ligand is a type II transmembrane protein constitutively expressed by monocytes, B cells and neuroblastoma cells (1). Binding of CD137 (4-1BB) to CD137L induces monocyte activation (2). Human CD137L-muCD8 binds to CD137 on human cells and is blocked by CD137-huIg fusion protein.||Functional Application: Human CD137L-muCD8 binds to CD137 and blocks binding of anti-CD137 monoclonal antibody.||Human CD137L-muCD8 Fusion Protein*||Molecular Structure: A soluble fusion protein consisting of the extracellular domain (184aa) of human CD137 Ligand fused to the extracellular domain (167aa) of murine CD8 alpha.||Transfectant Cell Line: CHO||Applications: |Suitable for use in ELISA, Flow cytometry. Other applications not tested.||Recommended Dilution|Optimal dilutions to be determined by the researcher.||Storage and Stability:|May be stored at 4°C. For long-term storage, aliquot and store at 4°C. Do not freeze. Aliquots are stable for at least 6 months. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.|

Applications
Source: CHO cells|Purity: Purified by affinity chromatography. |Concentration: ~0.5mg/ml|Form: Supplied as a liquid in FBS, 50mM Tris 150mM NaCl 1mM Spermidine pH 8.0, 0.2% BSA, 0.5 mg/ml Gentamicin Sulfate.||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Form
Supplied as a liquid in FBS, 50mM Tris 150mM NaCl 1mM Spermidine pH 8.0, 0.2% BSA, 0.5 mg/ml Gentamicin Sulfate.
Purity
Purified by affinity chromatography.
References
1) M.R. Alderson, et al, (1994) Eur J Immunol 24: 2219-2227. |2) J. Langstein, et al, (1998) J Immunol 160: 2488-2494.|